{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T20:00:37Z","timestamp":1720382437581},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.leukres.2015.11.004","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T06:11:47Z","timestamp":1446703907000},"page":"10-16","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Response of patients with indolent systemic mastocytosis to tamoxifen citrate"],"prefix":"10.1016","volume":"40","author":[{"given":"Joseph H.","family":"Butterfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"January (1)","key":"10.1016\/j.leukres.2015.11.004_bib0005","first-page":"1","article-title":"Systemic mastocytosis: management of an unusual case with histamine (H1 and H2) antagonists and cyclooxygenase inhibition","volume":"10","author":"Crawhall","year":"1987","journal-title":"Clin. Invest. Med."},{"issue":"January (1)","key":"10.1016\/j.leukres.2015.11.004_bib0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(85)90454-1","article-title":"Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial","volume":"78","author":"Frieri","year":"1985","journal-title":"Am. J. Med."},{"issue":"May (5)","key":"10.1016\/j.leukres.2015.11.004_bib0015","doi-asserted-by":"crossref","first-page":"769","DOI":"10.7326\/0003-4819-90-5-769","article-title":"Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis","volume":"90","author":"Hirschowitz","year":"1979","journal-title":"Ann. Intern. Med."},{"issue":"October (7)","key":"10.1016\/j.leukres.2015.11.004_bib0020","first-page":"684","article-title":"Systemic mastocytosis: control of lifelong diarrhea by ingested disodium cromoglycate","volume":"111","author":"Dolovich","year":"1974","journal-title":"Can. Med. Assoc. J."},{"issue":"March (3)","key":"10.1016\/j.leukres.2015.11.004_bib0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/rheumatology\/36.3.393","article-title":"The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis","volume":"36","author":"Marshall","year":"1997","journal-title":"Br. J. Rheumatol."},{"issue":"October (4)","key":"10.1016\/j.leukres.2015.11.004_bib0030","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/0002-9343(80)90476-3","article-title":"The effect of cimetidine and propantheline on the symptoms of a patient with systemic mastocytosis","volume":"69","author":"Achord","year":"1980","journal-title":"Am. J. Med."},{"issue":"August (3)","key":"10.1016\/j.leukres.2015.11.004_bib0035","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.iac.2006.05.002","article-title":"Diagnostic evaluation and classification of mastocytosis","volume":"26","author":"Valent","year":"2006","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"February (9)","key":"10.1016\/j.leukres.2015.11.004_bib0040","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"January (4)","key":"10.1016\/j.leukres.2015.11.004_bib0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"August (9383)","key":"10.1016\/j.leukres.2015.11.004_bib0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"issue":"December (21)","key":"10.1016\/j.leukres.2015.11.004_bib0055","article-title":"Midostaurin (PKC412) demonstrates a high rate of durable responses in patients with advanced systemic mastocytosis: results from the fully accrued global phase 2CPKC412D2201 Trial [abstract]","volume":"124","author":"Gotlib","year":"2014","journal-title":"Blood"},{"issue":"July (1)","key":"10.1016\/j.leukres.2015.11.004_bib0060","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"issue":"March (3)","key":"10.1016\/j.leukres.2015.11.004_bib0065","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.leukres.2008.06.013","article-title":"Lenalidomide therapy in systemic mastocytosis","volume":"33","author":"Kluin-Nelemans","year":"2009","journal-title":"Leuk. Res."},{"issue":"March (3)","key":"10.1016\/j.leukres.2015.11.004_bib0070","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3109\/10428190903470869","article-title":"Treatment of aggressive systemic mastocytosis with daclizumab","volume":"51","author":"Quintas-Cardama","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"February (2)","key":"10.1016\/j.leukres.2015.11.004_bib0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/10428190903486220","article-title":"Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis","volume":"51","author":"Parikh","year":"2010","journal-title":"Leuk. Lymphoma"},{"issue":"November (5)","key":"10.1016\/j.leukres.2015.11.004_bib0080","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jaci.2003.07.004","article-title":"Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation","volume":"112","author":"Duffy","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.leukres.2015.11.004_bib0085","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"291","article-title":"Mastocytosis (mast cell disease)","author":"Valent","year":"2001"},{"issue":"October (10)","key":"10.1016\/j.leukres.2015.11.004_bib0090","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1038\/leu.2013.227","article-title":"Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"January (1)","key":"10.1016\/j.leukres.2015.11.004_bib0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0378-4347(98)00481-2","article-title":"Determination of 1-methylhistamine and 1-methylimidazoleacetic acid in human urine as a tool for the diagnosis of mastocytosis","volume":"721","author":"Martens-Lobenhoffer","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.leukres.2015.11.004_bib0100","series-title":"SF-36 Health Survey: Manual and Interpretation Guide","author":"Ware","year":"1993"},{"issue":"May (5)","key":"10.1016\/j.leukres.2015.11.004_bib0105","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med. Care"},{"issue":"July (2)","key":"10.1016\/j.leukres.2015.11.004_bib0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"issue":"November (11)","key":"10.1016\/j.leukres.2015.11.004_bib0115","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk. Res."},{"issue":"June (12)","key":"10.1016\/j.leukres.2015.11.004_bib0120","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2015.11.004_bib0125","first-page":"3536","article-title":"The KIT tyrosine kinase inhibitor midostraurine (PKC412) exhibits a high response rate in aggressive systemic mastocytosis (ASM): interim results of a phase II trial [abstract]","volume":"110","author":"Gotlib","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.leukres.2015.11.004_bib0130","series-title":"Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics","first-page":"1256","article-title":"Antineoplastic agents","author":"Calabresi","year":"2015"},{"issue":"November (9)","key":"10.1016\/j.leukres.2015.11.004_bib0135","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood.V84.9.2954.2954","article-title":"Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation","volume":"84","author":"Fodinger","year":"1994","journal-title":"Blood"},{"issue":"January (1)","key":"10.1016\/j.leukres.2015.11.004_bib0140","first-page":"5","article-title":"New insights into the riddle of the mast cells: microenvironmental regulation of mast cell development and phenotypic heterogeneity","volume":"62","author":"Galli","year":"1990","journal-title":"Lab. Invest."},{"issue":"February (2)","key":"10.1016\/j.leukres.2015.11.004_bib0145","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.leukres.2004.05.003","article-title":"Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case","volume":"29","author":"Butterfield","year":"2005","journal-title":"Leuk. Res."},{"issue":"February (2)","key":"10.1016\/j.leukres.2015.11.004_bib0150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","article-title":"Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2015.11.004_bib0155","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/S0091-6749(99)70156-9","article-title":"Response to cyclosporin and low-dose methylprednisolone in aggressive systemic mastocytosis","volume":"103","author":"Kurosawa","year":"1999","journal-title":"J. Allergy Clin. Immunol."},{"issue":"April (7)","key":"10.1016\/j.leukres.2015.11.004_bib0160","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1158\/1078-0432.CCR-03-0538","article-title":"Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial","volume":"10","author":"Kisanga","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"September (18)","key":"10.1016\/j.leukres.2015.11.004_bib0165","first-page":"4837","article-title":"Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment","volume":"51","author":"Lien","year":"1991","journal-title":"Cancer Res."},{"issue":"September (9)","key":"10.1016\/j.leukres.2015.11.004_bib0170","first-page":"2366","article-title":"A phase II. study of high-dose tamoxifen in patients with hormone-refractory prostate cancer","volume":"5","author":"Bergan","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.leukres.2015.11.004_bib0175","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000236217","article-title":"Estradiol augments while tamoxifen inhibits rat mast cell secretion","volume":"98","author":"Vliagoftis","year":"1992","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.leukres.2015.11.004_bib0180","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/0006-291X(85)91302-6","article-title":"Evidence that tamoxifen is a histamine antagonist","volume":"131","author":"Kroeger","year":"1985","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T23:56:03Z","timestamp":1599782163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615305439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":36,"alternative-id":["S0145212615305439"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.11.004","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response of patients with indolent systemic mastocytosis to tamoxifen citrate","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}